skip to main content

CDK4 Liposarcoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateSarcomaCDK4 LiposarcomaSCE Medical Oncology

A 62-year-old woman with sarcoma (DDLPS) has MDM2 and CDK4 co-amplification. A clinical trial testing abemaciclib (CDK4 inhibitor) is available. What is the rationale?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — CDK4 is co-amplified with MDM2 in ~90% of WDLPS/DDLPS; CDK4 inhibitors (abemaciclib, palbociclib) directly target this amplification — CDK4i trials in liposarcoma represent precision oncology for this molecular subtype

CDK4 amplified in ~90% WDLPS/DDLPS (co-amplified with MDM2). CDK4 inhibitors directly target this. Ongoing trials evaluating abemaciclib and other CDK4i in MDM2/CDK4-amplified liposarcoma.

Reference: ESMO 2024 STS; Dickson et al JCO 2016